Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BT524

Plasma-derived product · Protein replacement · developed by Biotest

Phase 3 Most advanced trial (none active)
1 Registered trials

What is BT524?

BT524 is a human fibrinogen concentrate given by intravenous infusion, with dosing based on body weight and fibrinogen level. It is studied in congenital afibrinogenemia and congenital hypofibrinogenemia, conditions in which patients lack or have low levels of fibrinogen.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Human Fibrinogen Concentrate
Drug type
Plasma-derived product
Mechanism
Protein replacement
Pathways
blood coagulation
Therapy area
Hematology
Developer
Biotest
In trials of
ICLR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02065882 Phase 3 Congenital Afibrinogenemia Completed ICLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital AfibrinogenemiaCongenital Hypofibrinogenemia

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.